Gerresheimer (GXI.DE) Stock Price
Gerresheimer Price
Over the last 19 years Gerresheimer grew revenue by 7.0% annually, reaching 2.32 B EUR. Earnings per share have grown at 33.2% per year over the last 17 years. For Gerresheimer, the net margin of -13.8% is down versus 5.6% a few years ago. At today's price the dividend yield works out to roughly 0.13%. The consensus 12-month price target for Gerresheimer is 23.46 EUR, about 24.3% below where the stock trades today. Of 23 analysts, 4 rate the stock a buy — an overall Hold consensus.
Gerresheimer stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Gerresheimer business model & stock analysis
Frequently asked questions about Gerresheimer
Gerresheimer AG is a global leader in the manufacturing of high-quality pharmaceutical packaging and drug delivery systems. The company specializes in producing glass and plastic containers, primary packaging solutions, and innovative drug delivery systems for the pharmaceutical and healthcare industry. With a strong focus on quality, safety, and sustainability, Gerresheimer AG serves as a reliable partner for the healthcare sector, providing advanced packaging solutions that ensure the integrity and stability of medications and treatments. By catering to the specific needs of pharmaceutical companies worldwide, Gerresheimer AG plays a critical role in supporting the safe and effective delivery of healthcare products.
Gerresheimer AG is primarily active in the pharmaceutical and healthcare industry. With over 150 years of experience, Gerresheimer specializes in manufacturing and supplying high-quality packaging and drug delivery systems for medications, such as glass and plastic containers, syringes, and inhalers. The company serves pharmaceutical companies worldwide, enabling safe and efficient drug storage, transportation, and administration. With a strong focus on innovation and customer satisfaction, Gerresheimer AG continues to play a significant role in the healthcare sector, ensuring the integrity and effectiveness of medical products throughout the supply chain.
The main competitors of Gerresheimer AG in the market are SCHOTT AG, Stevanato Group, and Berry Global Inc.
Gerresheimer AG, headquartered in Düsseldorf, Germany, is a global manufacturer of specialized packaging and delivery systems for the pharmaceuticals and healthcare industries. With a rich history dating back to 1864, Gerresheimer has evolved to become a leading provider of high-quality glass and plastic packaging solutions. The company's diverse product portfolio includes ampoules, vials, syringes, inhalers, and various innovative drug delivery systems. Gerresheimer operates worldwide, serving customers in over 100 countries, and has production facilities in Europe, North and South America, and Asia. Committed to innovation, sustainability, and customer satisfaction, Gerresheimer has established a strong reputation in the pharmaceutical packaging industry.
Gerresheimer AG has achieved several significant milestones throughout its history. One notable achievement occurred in 2007 when the company successfully completed its IPO and became a publicly traded entity on the Frankfurt Stock Exchange. Additionally, Gerresheimer AG has established a strong global presence, expanding its operations to various countries including the United States, China, and Brazil. The company has also received several industry recognitions, such as the German Packaging Award, for its innovative packaging solutions. Moreover, Gerresheimer AG continuously focuses on research and development to drive technological advancements in the pharmaceutical and healthcare sectors. These milestones highlight Gerresheimer AG's commitment to innovation, global expansion, and maintaining a leading position in the market.
Gerresheimer AG is primarily present in multiple countries and regions across the globe. It has a strong presence in Europe, including Germany, France, Italy, and Spain. Additionally, Gerresheimer AG has a significant market share in North America, with operations in the United States and Canada. The company also has a growing presence in Asia, specifically in China and India, where it caters to a wide range of customers. With its expanding global footprint, Gerresheimer AG ensures its products and services reach customers in various countries and regions, reaffirming its status as a leading player in the industry.
Gerresheimer AG represents a strong set of values and corporate philosophy. With a focus on precision, quality, and innovation, Gerresheimer AG aims to provide cutting-edge solutions in the field of pharmaceutical and healthcare packaging. The company prides itself on sustainability, aiming to minimize its environmental impact while ensuring the highest standards of product safety. Gerresheimer AG values teamwork, integrity, and open communication, fostering a collaborative and inclusive work environment. With a customer-centric approach, the company strives to meet the diverse needs of its clients globally. Gerresheimer AG's commitment to excellence and continuous improvement solidifies its position as a leading provider in the healthcare industry.
Analysts currently set an average price target of 32.54 EUR for the Gerresheimer stock (median: 23.46 EUR), implying +1.7 % versus the latest price. The consensus is based on 23 analyst ratings.
22 analysts currently rate the Gerresheimer stock: 4 recommend buying, 9 holding and 9 selling. For 2026, analysts expect Gerresheimer to generate revenue of 2.34 B EUR and earnings per share of 1.71 EUR.
The Gerresheimer share (GXI.DE) is listed on 9 stock exchanges, including: London (0NTI.L), SIX (Zürich) (GXI.SW), XETRA (GXI.DE), Frankfurt (GXI.F), München (GXI.MU), Düsseldorf (GXI.DU), Hamburg (GXI.HM), Wien (GXI.VI).
Gerresheimer AG is a leading provider of high-quality packaging and system solutions for the pharmaceutical and medical industries, as well as for the cosmetics and food industries. The company is headquartered in Düsseldorf and employs over 10,000 people worldwide. The business activities of Gerresheimer AG are divided into three segments: Pharma & Healthcare, Plastics & Devices, and Primary Packaging Glass. Each segment offers specific products and services. In the Pharma & Healthcare segment, Gerresheimer AG offers complete solutions such as syringes, insulin pens, and inhalers. In addition, the company manufactures medical products such as test tubes, blood sample containers, and ampoules. These products are developed and designed in close cooperation with customers to ensure safety and reliability. With its ability to manufacture precision instruments and complex systems, Gerresheimer AG is a preferred partner of the pharmaceutical industry. The Plastics & Devices segment of Gerresheimer AG offers plastic products for medical devices. The range includes primarily injection molded products that enable continuous and precise dosing of medications. Their plastic products are developed and manufactured according to the highest quality standards. Primary Packaging Glass, the third segment of the company, specializes in the production and processing of glass. The company manufactures bottles, ampoules, and glassware for the pharmaceutical and cosmetic industries, as well as the food and beverage industry. The packaging solutions meet the highest requirements for hygiene, safety, and durability. Due to the COVID-19 pandemic and the global spread of the virus, the demand for pharmaceutical and medical products has increased significantly. This has helped Gerresheimer AG further expand its strong performance in this industry. The capacity increases at the main locations have enabled the company to meet the demand for syringes and other medical devices. To further strengthen its market position, Gerresheimer AG is heavily investing in research and development as well as the efficient use of modern production processes. The company works closely with key customers to address the specific needs of the industries and develop innovative solutions. In conclusion, Gerresheimer AG's business model specializes in products that meet demanding customer requirements and industry demands. The continuous investment in research and development, as well as modern technologies, allows the company to maintain a leading position in the industry and continuously expand its business to respond to changing customer needs.
The expected revenue of Gerresheimer is 2.34 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Gerresheimer is 58.91 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Gerresheimer is currently 18.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Gerresheimer stock.
The price-to-sales ratio (P/S) of Gerresheimer is currently 0.46. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Gerresheimer stock.
The Eulerpool Quality Score for Gerresheimer is 4/10.
The ISIN of Gerresheimer is DE000A0LD6E6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Gerresheimer is A0LD6E. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Gerresheimer is GXI.DE. The ticker symbol is used to trade Gerresheimer shares on the stock exchange.
Gerresheimer stock
All fundamentals and in-depth analysis of Gerresheimer
Our stock analysis for Gerresheimer stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gerresheimer. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.